- Home
- DLHC vs PBYI Comparison
DLHC vs PBYI Comparison
Compare DLHC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- PBYI
- Stock Information
- Founded
- DLHC 1969
- PBYI 2010
- Country
- DLHC United States
- PBYI United States
- Employees
- DLHC N/A
- PBYI N/A
- Industry
- DLHC Business Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- PBYI Health Care
- Exchange
- DLHC Nasdaq
- PBYI Nasdaq
- Market Cap
- DLHC 117.4M
- PBYI 126.5M
- IPO Year
- DLHC N/A
- PBYI N/A
- Fundamental
- Price
- DLHC $8.53
- PBYI $3.00
- Analyst Decision
- DLHC
- PBYI Strong Buy
- Analyst Count
- DLHC 0
- PBYI 1
- Target Price
- DLHC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- DLHC 55.7K
- PBYI 583.8K
- Earning Date
- DLHC 12-04-2024
- PBYI 11-07-2024
- Dividend Yield
- DLHC N/A
- PBYI N/A
- EPS Growth
- DLHC N/A
- PBYI 492.79
- EPS
- DLHC 0.17
- PBYI 0.47
- Revenue
- DLHC $401,038,000.00
- PBYI $243,569,000.00
- Revenue This Year
- DLHC $8.70
- PBYI N/A
- Revenue Next Year
- DLHC $6.10
- PBYI N/A
- P/E Ratio
- DLHC $48.90
- PBYI $6.44
- Revenue Growth
- DLHC 17.39
- PBYI 6.30
- 52 Week Low
- DLHC $7.94
- PBYI $2.23
- 52 Week High
- DLHC $17.58
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- DLHC 47.54
- PBYI 54.18
- Support Level
- DLHC $8.18
- PBYI $2.32
- Resistance Level
- DLHC $8.62
- PBYI $3.25
- Average True Range (ATR)
- DLHC 0.36
- PBYI 0.33
- MACD
- DLHC 0.01
- PBYI -0.01
- Stochastic Oscillator
- DLHC 35.98
- PBYI 57.14
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. It is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, and telehealth systems.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.